Behind the Paper

The real stories behind the latest research papers, from conception to publication, the highs and the lows

Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection – the Antibody Mediated Prevention (AMP) trials

A new biomarker appears to be an effective surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1. Broadly neutralizing antibodies (bnAbs) are defined by their ability to neutralize multiple genetically distinct viral strains.
Go to the profile of Elena E. Giorgi
Aug 25, 2022